Review

February 28, 2024


Liver sinusoidal endothelial cell: An important yet often overlooked player in the liver fibrosis
Jiaorong Qu, Le Wang, Yufei Li, et al.
Clin Mol Hepatol. 2024;30(3):303-325.

Review

April 26, 2024


Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication
Chung-Feng Huang, Manar Hijaze Awad, Meital Gal-Tanamy, et al.
Clin Mol Hepatol. 2024;30(3):326-344.

Original Article

March 12, 2024


Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study
Young Eun Chon, Dong Yun Kim, Mi Na Kim, et al.
Clin Mol Hepatol. 2024;30(3):345-359.

Original Article

March 15, 2024


Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma
Jiwon Hong, Jung Woo Eun, Geum Ok Baek, et al.
Clin Mol Hepatol. 2024;30(3):360-374.

Original Article

March 26, 2024


Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients
Man-Fung Yuen, Wan-Long Chuang, Cheng-Yuan Peng, et al.
Clin Mol Hepatol. 2024;30(3):375-387.

Original Article

April 11, 2024


Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment
Do Seon Song, Hee Yeon Kim, Young Kul Jung, et al.
Clin Mol Hepatol. 2024;30(3):388-405.

Original Article

April 11, 2024


Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma
Chun-Ting Ho, Elise Chia-Hui Tan, Pei-Chang Lee, et al.
Clin Mol Hepatol. 2024;30(3):406-420.

Original Article

April 11, 2024


Ischemia-free liver transplantation improves the prognosis of recipients using functionally marginal liver grafts
Shuai Wang, Xiaohong Lin, Yunhua Tang, et al.
Clin Mol Hepatol. 2024;30(3):421-435.

Original Article

April 16, 2024


Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis
Harry Crane, Guy D. Eslick, Cameron Gofton, et al.
Clin Mol Hepatol. 2024;30(3):436-448.

Original Article

April 16, 2024


Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease
Yiyuan Zheng, Lina Zhao, Zhekun Xiong, et al.
Clin Mol Hepatol. 2024;30(3):449-467.

Original Article

April 19, 2024


Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy
Pei-Chien Tsai, Chung-Feng Huang, Ming-Lun Yeh, et al.
Clin Mol Hepatol. 2024;30(3):468-486.

Original Article

May 7, 2024


Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study
Seogsong Jeong, Yun Hwan Oh, Joseph C Ahn, et al.
Clin Mol Hepatol. 2024;30(3):487-499.

Original Article

May 10, 2024


Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study
Moon Haeng Hur, Dong Hyeon Lee, Jeong-Hoon Lee, et al.
Clin Mol Hepatol. 2024;30(3):500-514.

Original Article

May 10, 2024


Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy
Qi Wang, Qingfa Bu, Zibo Xu, et al.
Clin Mol Hepatol. 2024;30(3):515-538.

Original Article

May 14, 2024


Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction
Mehrangiz Dezhbord, Seong Ho Kim, Soree Park, et al.
Clin Mol Hepatol. 2024;30(3):539-560.

Original Article

June 3, 2024


Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis
Juchul Hwang, Hyeyoung Hwang, Hyunjae Shin, et al.
Clin Mol Hepatol. 2024;30(3):561-576.


"Most viewed" articles are from the articles published during the last six months

Original Article
1873
Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Miguel Sogbe, Idoia Bilbao, Francesco P. Marchese, Jon Zazpe, Annarosaria De Vito, Marta Pozuelo, Delia D’Avola, Mercedes Iñarrairaegui, Carmen Berasain, Maria Arechederra, Josepmaria Argemi, Bruno Sangro
Clin Mol Hepatol. 2024;30(2):177-190.   Published online December 29, 2023
View: 6910   Download: 262  Web of Science: 2  Crossref: 3
Review
1735
MAFLD: How is it different from NAFLD?
Cameron Gofton, Yadhavan Upendran, Ming-Hua Zheng, Jacob George
Clin Mol Hepatol. 2023;29(Suppl):S17-S31.   Published online November 29, 2022
View: 14037   Download: 1,104  Web of Science: 72  Crossref: 91
Snapshot
1874
Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Xinyi Lu, Rui Yang, Yu Chen, Daozhen Chen
Clin Mol Hepatol. 2024;30(3):582-584.   Published online December 29, 2023
View: 5537   Download: 65
Original Article
1814
Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Yee Hui Yeo, Jamil S. Samaan, Wee Han Ng, Peng-Sheng Ting, Hirsh Trivedi, Aarshi Vipani, Walid Ayoub, Ju Dong Yang, Omer Liran, Brennan Spiegel, Alexander Kuo
Clin Mol Hepatol. 2023;29(3):721-732.   Published online March 22, 2023
View: 17007   Download: 1,512  Web of Science: 155  Crossref: 176
Review
1748
Global incidence and prevalence of nonalcoholic fatty liver disease
Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Eunice Tan, Mark D. Muthiah
Clin Mol Hepatol. 2023;29(Suppl):S32-S42.   Published online December 14, 2022
View: 10663   Download: 446  Web of Science: 91  Crossref: 117
Guideline
1713
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Clin Mol Hepatol. 2022;28(4):583-705.   Published online October 1, 2022
View: 11985   Download: 718  Web of Science: 107  Crossref: 113
Original Article
1881
Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis
Michael H. Le, David M. Le, Thomas C. Baez, Hansen Dang, Vy H. Nguyen, KeeSeok Lee, Christopher D. Stave, Takanori Ito, Yuankai Wu, Yee Hui Yeo, Fanpu Ji, Ramsey Cheung, Mindie H. Nguyen
Clin Mol Hepatol. 2024;30(2):235-246.   Published online January 26, 2024
View: 3628   Download: 232  Web of Science: 3  Crossref: 4
1877
JCAD deficiency attenuates activation of hepatic stellate cells and cholestatic fibrosis
Li Xie, Hui Chen, Li Zhang, Yue Ma, Yuan Zhou, Yong-Yu Yang, Chang Liu, Yu-Li Wang, Ya-Jun Yan, Jia Ding, Xiao Teng, Qiang Yang, Xiu-Ping Liu, Jian Wu
Clin Mol Hepatol. 2024;30(2):206-224.   Published online January 8, 2024
View: 3441   Download: 188  Web of Science: 4  Crossref: 4
1879
Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study
Michihiro Iwaki, Hideki Fujii, Hideki Hayashi, Hidenori Toyoda, Satoshi Oeda, Hideyuki Hyogo, Miwa Kawanaka, Asahiro Morishita, Kensuke Munekage, Kazuhito Kawata, Tsubasa Tsutsumi, Koji Sawada, Tatsuji Maeshiro, Hiroshi Tobita, Yuichi Yoshida, Masafumi Naito, Asuka Araki, Shingo Arakaki, Takumi Kawaguchi, Hidenao Noritake, Masafumi Ono, Tsutomu Masaki, Satoshi Yasuda, Eiichi Tomita, Masato Yoneda, Akihiro Tokushige, Yoshihiro Kamada, Hirokazu Takahashi, Shinichiro Ueda, Shinichi Aishima, Yoshio Sumida, Atsushi Nakajima, Takeshi Okanoue
Clin Mol Hepatol. 2024;30(2):225-234.   Published online January 24, 2024
View: 3389   Download: 195  Web of Science: 4  Crossref: 4
1712
Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Michael H. Le, Yee Hui Yeo, Biyao Zou, Scott Barnet, Linda Henry, Ramsey Cheung, Mindie H. Nguyen
Clin Mol Hepatol. 2022;28(4):841-850.   Published online September 19, 2022
View: 7122   Download: 247  Web of Science: 76  Crossref: 81
1880
Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression
Sumin Oh, Yang-Hyun Baek, Sungju Jung, Sumin Yoon, Byeonggeun Kang, Su-hyang Han, Gaeul Park, Je Yeong Ko, Sang-Young Han, Jin-Sook Jeong, Jin-Han Cho, Young-Hoon Roh, Sung-Wook Lee, Gi-Bok Choi, Yong Sun Lee, Won Kim, Rho Hyun Seong, Jong Hoon Park, Yeon-Su Lee, Kyung Hyun Yoo
Clin Mol Hepatol. 2024;30(2):247-262.   Published online January 26, 2024
View: 2900   Download: 201  Web of Science: 2  Crossref: 2
Review
1684
Management of refractory ascites
Florence Wong
Clin Mol Hepatol. 2023;29(1):16-32.   Published online June 9, 2022
View: 10203   Download: 890  Web of Science: 12  Crossref: 12
Original Article
1876
Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients
Jinlin Hou, Edward Gane, Rozalina Balabanska, Wenhong Zhang, Jiming Zhang, Tien Huey Lim, Qing Xie, Chau-Ting Yeh, Sheng-Shun Yang, Xieer Liang, Piyawat Komolmit, Apinya Leerapun, Zenghui Xue, Ethan Chen, Yuchen Zhang, Qiaoqiao Xie, Ting-Tsung Chang, Tsung-Hui Hu, Seng Gee Lim, Wan-Long Chuang, Barbara Leggett, Qingyan Bo, Xue Zhou, Miriam Triyatni, Wen Zhang, Man-Fung Yuen
Clin Mol Hepatol. 2024;30(2):191-205.   Published online January 8, 2024
View: 2913   Download: 177  Web of Science: 1  Crossref: 1
Review
1714
Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Kuei-Chuan Lee, Pei-Shan Wu, Han-Chieh Lin
Clin Mol Hepatol. 2023;29(1):77-98.   Published online October 13, 2022
View: 9864   Download: 653  Web of Science: 40  Crossref: 47
Original Article
1871
Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets
Yingzhou Shi, Hang Dong, Shiwei Sun, Xiaoqin Wu, Jiansong Fang, Jianbo Zhao, Junming Han, Zongyue Li, Huixiao Wu, Luna Liu, Wanhong Wu, Yang Tian, Guandou Yuan, Xiude Fan, Chao Xu
Clin Mol Hepatol. 2024;30(1):80-97.   Published online December 7, 2023
View: 3881   Download: 184  Web of Science: 2  Crossref: 2
Review
1875
Comprehensive approach to controlling chronic hepatitis B in China
Shan Shan, Xinyan Zhao, Jidong Jia
Clin Mol Hepatol. 2024;30(2):135-143.   Published online January 5, 2024
View: 2769   Download: 186
Editorial
Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization
Mohammad Saeid Rezaee-Zavareh, Naomy Kim, Ju Dong Yang
Clin Mol Hepatol. 2024;30(2):150-153.   Published online February 22, 2024
View: 2512   Download: 71  Web of Science: 1  Crossref: 1
Review
1858
Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases
Pin-Nan Cheng, Wen-Jone Chen, Charles Jia-Yin Hou, Chih-Lin Lin, Ming-Ling Chang, Chia-Chi Wang, Wei-Ting Chang, Chao-Yung Wang, Chun-Yen Lin, Chung-Lieh Hung, Cheng-Yuan Peng, Ming-Lung Yu, Ting-Hsing Chao, Jee-Fu Huang, Yi-Hsiang Huang, Chi-Yi Chen, Chern-En Chiang, Han-Chieh Lin, Yi-Heng Li, Tsung-Hsien Lin, Jia-Horng Kao, Tzung-Dau Wang, Ping-Yen Liu, Yen-Wen Wu, Chun-Jen Liu
Clin Mol Hepatol. 2024;30(1):16-36.   Published online October 4, 2023
View: 3973   Download: 282  Web of Science: 3  Crossref: 3
Original Article
1868
Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program
Ming-Ying Lu, Chung-Feng Huang, Chao-Hung Hung, Chi‐Ming Tai, Lein-Ray Mo, Hsing-Tao Kuo, Kuo-Chih Tseng, Ching-Chu Lo, Ming-Jong Bair, Szu-Jen Wang, Jee-Fu Huang, Ming-Lun Yeh, Chun-Ting Chen, Ming-Chang Tsai, Chien-Wei Huang, Pei-Lun Lee, Tzeng-Hue Yang, Yi-Hsiang Huang, Lee-Won Chong, Chien-Lin Chen, Chi-Chieh Yang, Sheng‐Shun Yang, Pin-Nan Cheng, Tsai-Yuan Hsieh, Jui-Ting Hu, Wen-Chih Wu, Chien-Yu Cheng, Guei-Ying Chen, Guo-Xiong Zhou, Wei-Lun Tsai, Chien-Neng Kao, Chih-Lang Lin, Chia-Chi Wang, Ta-Ya Lin, Chih‐Lin Lin, Wei-Wen Su, Tzong-Hsi Lee, Te-Sheng Chang, Chun-Jen Liu, Chia-Yen Dai, Jia-Horng Kao, Han-Chieh Lin, Wan-Long Chuang, Cheng-Yuan Peng, Chun-Wei- Tsai, Chi-Yi Chen, Ming-Lung Yu
Clin Mol Hepatol. 2024;30(1):64-79.   Published online November 21, 2023
View: 3072   Download: 108  Crossref: 1
Review
Non-alcoholic fatty liver disease: Definition and subtypes
Seul Ki Han, Soon Koo Baik, Moon Young Kim
Clin Mol Hepatol. 2023;29(suppl):S5-S16.   Published online December 28, 2022
View: 7016   Download: 500  Web of Science: 35  Crossref: 36
Snapshot
1887
Immunopathogenesis of liver fibrosis in steatotic liver disease
Chaerin Woo, Won-Il Jeong
Clin Mol Hepatol. 2024;30(2):299-302.   Published online February 19, 2024
View: 2085   Download: 83
Review
1842
Recent advances in the management of hepatocellular carcinoma
Kamya Sankar, Jun Gong, Arsen Osipov, Steven A. Miles, Kambiz Kosari, Nicholas N. Nissen, Andrew E. Hendifar, Ekaterina K. Koltsova, Ju Dong Yang
Clin Mol Hepatol. 2024;30(1):1-15.   Published online July 21, 2023
View: 6033   Download: 304  Web of Science: 7  Crossref: 8
Correspondence
Correspondence on Letter regarding “Toward hepatitis C virus elimination using artificial intelligence”
Ming-Ying Lu, Ming-Lung Yu
Clin Mol Hepatol. 2024;30(2):274-275.   Published online March 5, 2024
View: 1993   Download: 31  Crossref: 1
Editorial
Toward hepatitis C virus elimination using artificial intelligence
Moon Haeng Hur, Jeong-Hoon Lee
Clin Mol Hepatol. 2024;30(2):147-149.   Published online February 23, 2024
View: 1977   Download: 67  Crossref: 1
Review
1807
Acute-on-chronic liver failure: Terminology, mechanisms and management
Vinay Kumar BR, Shiv Kumar Sarin
Clin Mol Hepatol. 2023;29(3):670-689.   Published online March 20, 2023
View: 5795   Download: 670  Web of Science: 10  Crossref: 9
Editorial
Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer
Pin-Nan Cheng, Ming-Lung Yu
Clin Mol Hepatol. 2024;30(2):144-146.   Published online February 19, 2024
View: 1973   Download: 74  Crossref: 2
Letter to the Editor
1878
Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD
Hiroyuki Suzuki, Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Takumi Kawaguchi
Clin Mol Hepatol. 2024;30(2):263-265.   Published online January 18, 2024
View: 2107   Download: 122  Web of Science: 3  Crossref: 5
Editorial
The gene expression signature of metabolic dysfunction- associated steatotic liver disease from a multiomics perspective
Carlos Jose Pirola, Silvia Sookoian
Clin Mol Hepatol. 2024;30(2):174-176.   Published online February 5, 2024
View: 1960   Download: 59  Web of Science: 1  Crossref: 1
Review
Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region
Do Young Kim, Bao Nguyen Toan, Chee-Kiat Tan, Irsan Hasan, Lyana Setiawan, Ming-Lung Yu, Namiki Izumi, Nguyen Nguyen Huyen, Pierce Kah-Hoe Chow, Rosmawati Mohamed, Stephen Lam Chan, Tawesak Tanwandee, Teng-Yu Lee, Thi Thanh Nguyen Hai, Tian Yang, Woo-Chang Lee, Henry Lik Yuen Chan
Clin Mol Hepatol. 2023;29(2):277-292.   Published online January 30, 2023
View: 6839   Download: 513  Web of Science: 17  Crossref: 22

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

  • PubMed Central
  • PubMed
  • Scopus
  • KoreaMed
  • KoMCI
  • ScienceCentral
  • DOAJ
  • GoogleScholar
  • Similarity Check
  • Crossref Cited-by Linking
  • CrossMark
  • Funder Registry
  • Metadata
  • ORCID
  • MeSH on Demand
  • COPE
  • EMBASE
  • KOFST
  • ICMJE
  • Web of SCIENCE
Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 1034
TOTAL : 1939169
Close layer